Participants in the United States and the Netherlands completed an online survey that evaluated the impact of COVID-19 on situational circumstances, eating disorder symptoms, eating disorder treatment, and general well-being.
For adolescents with generalized anxiety disorder, escitalopram reduces symptoms of anxiety.
The most common subjects of worry were cancer, heart-related diseases, and neurological diseases.
Prevalence of GAD and depressive symptoms was significantly higher in participants younger than 35 years as compared to those aged 35 years or older.
Vortioxetine was more efficacious in people with generalized anxiety disorder who had higher levels of pre-treatment functioning.
